Effects of Anti-TNF alpha Therapy on Blood Pressure in Resistant Hypertensive Subjects: A Randomized, Double-Blind, Placebo-Controlled Pilot Study.
Ana Paula Cabral de FariaAlessandra M V RitterArthur Santa-CatharinaDébora P SouzaEstephania P NaseriManoel B BertoloMariana Rodrigues PioliCaio C CarvalhoRodrigo ModoloHeitor MorenoPublished in: Arquivos brasileiros de cardiologia (2021)
A single-dose of infliximab decreased the mean and diastolic BP levels immediately after its infusion, when compared to the placebo in RH. The anti-TNF-α therapy was found to be safe and well-tolerated. The results of this proof-of-concept are hypothesis-generating and need to be further investigated. (Arq Bras Cardiol. 2021; 116(3):443-451).
Keyphrases
- blood pressure
- placebo controlled
- double blind
- rheumatoid arthritis
- phase iii
- clinical trial
- hypertensive patients
- phase ii
- study protocol
- heart rate
- left ventricular
- squamous cell carcinoma
- low dose
- metabolic syndrome
- type diabetes
- atomic force microscopy
- mesenchymal stem cells
- radiation therapy
- stem cells
- cell therapy
- mass spectrometry
- ejection fraction
- bone marrow
- weight loss